• Department of Ophthalmology, People's Hospital, Peking University, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China;
Liang Jianhong, Email: jianhongliang@hotmail.com
Export PDF Favorites Scan Get Citation

Objective  To observe the effects of intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity (AP-ROP). Methods  It is a retrospective case study. Twenty-one patients (40 eyes) with AP-ROP were enrolled in this study. There were 9 males (18 eyes) and 12 females (22 eyes), with the mean gestational age of (28.30±1.79) weeks and the mean birth weight of (1 021.40±316.70) g. All the lesions of 40 eyes were located in posterior zone, with 24 eyes in zone I and 16 eyes in zone II. All the eyes were treated with intravitreal injection of conbercept 0.025 ml (0.25 mg). During follow-up, nonresponders or patients with deterioration were retreated with intravitreal injection of conbercept or photocoagulation; patients with progressive deterioration to stage 4 had received vitrectomy. At the 1, 2, 4, 8, 12, 16, 20, 24 weeks after treatments, the disappearance or decrease of retinal vessel tortuosity and neovascularization, and the growth of the normal retinal vessels toward the peripheral retina were evaluated. Results  Thirty-six eyes were cured for only one injection, the cured rate was 90.00%. However, 2 eyes (5.00%) had progressed to stage 4 with contractive retinal detachment, which underwent vitrectomy. Two eyes (5.00%) had received twice injections, whose remaining avascular zone area treated by photocoagulation. No major systemic or ocular complications after injection appeared. All lens remained transparent and no iatrogenic retinal hole was occurred during the follow-up. Conclusion  Intravitreal injection of conbercept is effective in the treatment of AP-ROP.

Citation: Cheng Yong, Liang Jianhong, Li Xiaoxin. Intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity. Chinese Journal of Ocular Fundus Diseases, 2017, 33(2): 144-147. doi: 10.3760/cma.j.issn.1005-1015.2017.02.008 Copy

  • Previous Article

    Intravitreal injection of bevacizumab or ranibizumab for the treatment of pathological myopia choroidal neovascularization
  • Next Article

    Visual field outcomes and refractive status of retinopathy of prematurity after laser treatment